{
    "clinical_study": {
        "@rank": "97581", 
        "acronym": "ASPECT-NP", 
        "arm_group": [
            {
                "arm_group_label": "Ceftolozane/tazobactam", 
                "arm_group_type": "Experimental", 
                "description": "ceftolozane/tazobactam IV 3000 mg every 8 hours for 8 days, or 14 days for Pseudomonas aeruginosa"
            }, 
            {
                "arm_group_label": "meropenem", 
                "arm_group_type": "Active Comparator", 
                "description": "meropenem IV 1000 mg every 8 hours for 8 days, or 14 for Pseudomonas aeruginosa"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3, Multicenter, Prospective, Randomized study of IV ceftolozane/tazobactam\n      vs. IV meropenem  in the treatment of adult patients with either Ventilator-Associated\n      Bacterial Pneumonia [VABP] or Ventilated Hospital-Acquired Bacterial Pneumonia [HABP]."
        }, 
        "brief_title": "Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia", 
        "condition": "Nosocomial Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Adult patients diagnosed with either VABP or ventilated HABP requiring IV antibiotic\n             therapy\n\n          2. Hospitalized for \u2265 48 hours, intubated and on mechanical ventilation at the time of\n             randomization;\n\n          3. APACHE II score between 15 and 35;\n\n          4. New or progressive infiltrate on chest radiography consistent with pneumonia\n\n          5. Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial\n             pneumonia\n\n        Key Exclusion Criteria:\n\n          1. History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics\n\n          2. Prior nonstudy antibiotics for > 24 hours\n\n          3. Gram-positive bacteria only on respiratory Gram stain.\n\n          4. Active immunosuppression\n\n          5. End-stage renal disease or requirement for dialysis;\n\n          6. Expected survival < 72 hours\n\n          7. Severe confounding respiratory condition (i.e., chest trauma with paradoxical\n             respiration)\n\n          8. Known or suspected community-acquired bacterial pneumonia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "726", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070757", 
            "org_study_id": "CXA-NP-11-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ceftolozane/tazobactam", 
                "description": "Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta(\u03b2)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.", 
                "intervention_name": "ceftolozane/tazobactam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "meropenem", 
                "description": "Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.", 
                "intervention_name": "Meropenem", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Merofit", 
                    "Monan", 
                    "Meronem", 
                    "Merrem"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Meropenem", 
                "Cephalosporins", 
                "Tazobactam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ventilator-associated bacterial pneumonia", 
            "Hospital-acquired bacterial pneumonia", 
            "Pneumonia", 
            "Lung Diseases", 
            "Respiratory Tract Diseases", 
            "Respiratory Tract Infections", 
            "Infection", 
            "Ventilator-Induced Lung Injury", 
            "Lung Injury"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia", 
        "overall_contact": {
            "email": "Jennifer.Kratz@INCResearch.com", 
            "last_name": "Jennifer Kratz", 
            "phone": "267-744-6226"
        }, 
        "overall_contact_backup": {
            "email": "Nicole.nygren@INCResearch.com", 
            "last_name": "Nicole Nygren", 
            "phone": "(661) 679-7879"
        }, 
        "overall_official": {
            "affiliation": "Cubist Pharmaceuticals", 
            "last_name": "Obiamiwe Umeh, M.D., MSc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Intent to Treat (ITT) population", 
            "measure": "All Cause Mortality", 
            "safety_issue": "Yes", 
            "time_frame": "Day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070757"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical response rates of ceftolozane/tazobactam versus meropenem in adult subjects with VNP.", 
                "safety_issue": "No", 
                "time_frame": "This will be assessed at the Test-of-cure (TOC) visit which is 7 to 14 days after the End of Therapy (EOT) visit"
            }, 
            {
                "measure": "Clinical response rates of ceftolozane/tazobactam versus meropenem in adult subjects with VNP.", 
                "safety_issue": "No", 
                "time_frame": "This will be assessed within 24 hours after EOT"
            }, 
            {
                "measure": "Clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in adult subjects with VNP.", 
                "safety_issue": "No", 
                "time_frame": "LFU occurs 28 to 35 days after EOT"
            }, 
            {
                "measure": "Per-pathogen microbiological response rates of ceftolozane/tazobactam versus meropenem at TOC.", 
                "safety_issue": "No", 
                "time_frame": "This will occur at the TOC which is 7-14 days after EOT"
            }, 
            {
                "measure": "Microbiological response rates of ceftolozane/tazobactam versus meropenem at EOT", 
                "safety_issue": "No", 
                "time_frame": "EOT visit occurs within 24 hours after last dose of study drug"
            }, 
            {
                "measure": "Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had P. aeruginosa from the baseline lower respiratory tract culture", 
                "safety_issue": "No", 
                "time_frame": "TOC is 7-14 days after EOT"
            }, 
            {
                "measure": "Day 14 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms", 
                "safety_issue": "Yes", 
                "time_frame": "Day 14"
            }, 
            {
                "measure": "Safety will be evaluated in the safety population by presenting summaries of deaths, AEs, laboratory evaluations, vital signs and physical exam in the 2 treatment groups", 
                "safety_issue": "Yes", 
                "time_frame": "All study visits through the LFU visit (28-35 days following the EOT visit)"
            }, 
            {
                "measure": "Pharmacokinetic parameters, such as maximum concentration achieved (Cmax), total exposure during one dosing interval (AUC0-\u03c4), steady-state volume of distribution (Vss) and Clearance (CLss)", 
                "safety_issue": "No", 
                "time_frame": "Day 4"
            }, 
            {
                "measure": "Day 28 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms in the Microbiological Intent-to-Treat (mITT) population", 
                "safety_issue": "Yes", 
                "time_frame": "Day 28"
            }, 
            {
                "measure": "Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had Enterobacteriaceae isolated from the baseline lower respiratory tract culture", 
                "safety_issue": "No", 
                "time_frame": "TOC visit is 7-14 days after EOT"
            }, 
            {
                "measure": "Per-pathogen clinical response at TOC by baseline minimum inhibitory concentration (MIC) and Kirby-Bauer zone diameter for ceftolozane/tazobactam versus meropenem", 
                "safety_issue": "No", 
                "time_frame": "TOC is 7-14 days after EOT"
            }
        ], 
        "source": "Cubist Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cubist Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}